EUVIMEDEUVIMED entdecken
Crossref

Matrix Metalloproteinase-Activatable Nanodrug Crossing Blood–Spinal Cord Barrier for On-Demand Drug Release in Spinal Cord Injury Repair

Bo Li iD, Tan Li, Qiaoyun Zhang, Liru Chen, Xintao Shuai iD, Bin Liu, Limin Rong

ACS Nano · 2026

DOI: 10.1021/acsnano.5c21926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Bo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Blood-Spinal Cord Barrier, Matrix Metalloproteinases, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Shenzhen Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methylprednisolone (MPS) has demonstrated considerable merits in the clinical treatment of spinal cord injury (SCI), yet its application is conspicuously constrained by the narrow therapeutic time window and grave side effects, such as gastrointestinal bleeding. Furthermore, the impediment posed by the blood-spinal cord barrier (BSCB) hinders the effective delivery of drugs to the injured tissue. In this study, we developed a nanodrug that exhibited programmed responsiveness to matrix metalloproteinases (MMPs) and reactive oxygen species (ROS). The surface peptide of the neutrally charged nanodrug was precisely tailored to be cleaved by MMPs at the SCI site, converting it to a robustly cationic entity, which facilitated efficient penetration of the BSCB. Subsequently, the encapsulated drugs underwent a swift release process within the SCI microenvironment, characterized by heightened ROS expression. The results showed that an impressive 7.42% of intravenously administered nanodrugs were successfully targeted to the lesion site, which inhibited cell apoptosis and fostered the survival of damaged neurons while concurrently mitigating the side effects compared to unmodified drugs. Besides, our investigation uncovered that MPS possessed the capability to modulate the polarization of macrophages, regulating the production of proinflammatory and anti-inflammatory cytokines, ultimately culminating in the restoration of motor function in injured mice. In essence, this ingeniously crafted nanodrug offers invaluable insights and guidance for the clinical management of SCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Cord InjuriesBlood-Spinal Cord BarrierMatrix MetalloproteinasesNanoparticlesMethylprednisoloneAnimalsMiceDrug LiberationReactive Oxygen SpeciesApoptosisFemale

Stichwörter der Autor:innen

blood−spinal cord barrierdrug deliverymethylprednisoloneprogrammed responsive nanodrugsspinal cord injury

Substanzen

Matrix MetalloproteinasesReactive Oxygen SpeciesMethylprednisolone

Autor:innen und Institutionen

  • Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical Uni…
  • Department of Endocrinology, The Eighth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 518033, China.
  • Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China.

ORCID-Profile: Bo Li, Xintao Shuai

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Natural Science Foundation of Shenzhen Municipality
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Li, B., Li, T., Zhang, Q., Chen, L., Shuai, X., Liu, B., & Rong, L. (2026). Matrix Metalloproteinase-Activatable Nanodrug Crossing Blood–Spinal Cord Barrier for On-Demand Drug Release in Spinal Cord Injury Repair. ACS Nano. https://doi.org/10.1021/acsnano.5c21926

Vancouver

Li B, Li T, Zhang Q, Chen L, Shuai X, Liu B, et al. Matrix Metalloproteinase-Activatable Nanodrug Crossing Blood–Spinal Cord Barrier for On-Demand Drug Release in Spinal Cord Injury Repair. ACS Nano. 2026. doi:10.1021/acsnano.5c21926

BibTeX
@article{Li2026,
  author = {Li, Bo and Li, Tan and Zhang, Qiaoyun and Chen, Liru and Shuai, Xintao and Liu, Bin and Rong, Limin},
  title = {Matrix Metalloproteinase-Activatable Nanodrug Crossing Blood–Spinal Cord Barrier for On-Demand Drug Release in Spinal Cord Injury Repair},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.5c21926}
}
Kostenlos starten →